Hilton Capital Management’s AstraZeneca AZN Stock Holding History

Hilton Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2M	Sell	53,609 -20,382	-28%	-$3.83M	0.69%	34
2026 Q1	$14.6M	Buy	73,991 +1,325	+2%	+$255K	1.1%	19
2025 Q4	$13.4M	Buy	72,666 +201	+0.3%	+$35.3K	1.01%	21
2025 Q3	$11.1M	Sell	72,465 -5,573	-7%	-$843K	0.9%	24
2025 Q2	$10.9M	Sell	78,038 -409	-0.5%	-$57.3K	0.87%	31
2025 Q1	$11.5M	Buy	78,447 +788	+1%	+$114K	0.98%	22
2024 Q4	$10.2M	Sell	77,659 -10,087	-11%	-$1.41M	0.88%	35
2024 Q3	$13.7M	Buy	87,746 +1,960	+2%	+$316K	1.06%	24
2024 Q2	$13.4M	Sell	85,786 -15,747	-16%	-$2.37M	1.13%	25
2024 Q1	$13.8M	Buy	101,533 +368	+0.4%	+$48.7K	1.23%	20
2023 Q4	$13.6M	Sell	101,165 -422	-0.4%	-$54.9K	1.46%	15
2023 Q3	$13.8M	Sell	101,587 -5,179	-5%	-$707K	1.83%	12
2023 Q2	$15.3M	Sell	106,766 -2,332	-2%	-$343K	1.84%	14
2023 Q1	$14.8M	Sell	109,098 -3,345	-3%	-$450K	1.94%	12
2022 Q4	$12.3M	Hold	112,443	–	–	1.62%	16
2022 Q3	$12.3M	Buy	112,443 +21,433	+24%	+$2.72M	1.62%	16
2022 Q2	$12M	Buy	91,010 +13,745	+18%	+$1.8M	1.48%	20
2022 Q1	$10.3M	Buy	+77,265	New	+$9.27M	1.1%	38

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Hilton Capital Management's AZN Position: Q2 2026 in Review

Hilton Capital Management reduced its AstraZeneca (AZN) stake by 28% in Q2 2026, selling an estimated $3.83M and leaving 53,609 shares worth $10.2M. The position accounts for 0.69% of the portfolio, ranked #34.

Hilton Capital Management first reported a position in AZN in Q1 2022 and has held it in 18 quarters since. The position peaked at $15.3M in Q2 2023. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Hilton Capital Management held 53,609 shares of AstraZeneca worth $10.2M as of Q2 2026.
Hilton Capital Management sold 20,382 AstraZeneca shares in Q2 2026, an estimated $3.83M.
AstraZeneca made up 0.69% of Hilton Capital Management's portfolio in Q2 2026, its #34 holding.
Hilton Capital Management first reported a position in AstraZeneca in Q1 2022 and has held it in 18 quarters since.
Hilton Capital Management's AstraZeneca position peaked at $15.3M in Q2 2023.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Hilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.